MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$2,617K
Free Cash flow
-$2,649K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Prepaid and other current assets
    • Share-based compensation
    • Net proceeds from issuance of co...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accounts payable, accrued liabil...
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,929
-4,489
-2,954
-4,249
Share-based compensation
214
364
225
1,001
Depreciation and amortization
3
2
15
44
Loss from equity method investment
-
-
0
0
Impairment of non-financial asset
-
-
127
-
Amortization/accretion on marketable securities
0
0
0
14
Allowance for credit losses
-
-
500
-
Accounts receivable
0
0
-3
1
Prepaid and other current assets
-396
-807
-335
-344
Other assets
-21
0
0
-50
Accounts payable, accrued liabilities and other liabilities
-354
233
-1,500
252
Net cash used in operating activities
-2,649
-3,083
-3,249
-3,342
Purchase of marketable securities
0
0
0
0
Sale of marketable securities
0
0
0
5,150
Investment in impilo therapeutics
-
-
0
-
Purchase of property and equipment
0
0
0
0
Investment in impilo therapeutics
-
-
-
0
Net cash provided by investing activities
0
0
0
5,150
Proceeds from exercise of options
0
124
0
0
Tax withholding payments on net share settlement equity awards
0
159
0
0
Proceeds from exercise of warrants
0
216
-
-
Net proceeds from issuance of common stock
29
0
205
353
Net cash provided by financing activities
29
181
205
353
Effect of exchange rate changes on cash
3
6
2
2
Net (decrease) increase in cash and cash equivalents
-2,617
-2,896
-3,042
2,163
Cash and cash equivalents at beginning of period
13,060
15,956
18,998
16,209
Cash and cash equivalents at end of period
10,443
13,060
15,956
18,998
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net proceeds fromissuance of common stock$29K (-89.86%↓ Y/Y)Net cash provided byfinancing activities$29K (-29.27%↓ Y/Y)Effect of exchange ratechanges on cash$3K (-57.14%↓ Y/Y)Net (decrease)increase in cash and cash...-$2,617K (-518.05%↓ Y/Y)Canceled cashflow$32K Prepaid and othercurrent assets-$396K (-528.57%↓ Y/Y)Share-based compensation$214K (-72.17%↓ Y/Y)Other assets-$21K (76.67%↑ Y/Y)Depreciation andamortization$3K (-96.55%↓ Y/Y)Net cash used inoperating activities-$2,649K (71.69%↑ Y/Y)Canceled cashflow$634K Net loss-$2,929K (68.78%↑ Y/Y)Accounts payable,accrued liabilities and...-$354K (73.22%↑ Y/Y)

LISATA THERAPEUTICS, INC. (LSTA)

LISATA THERAPEUTICS, INC. (LSTA)